Overview

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Janssen, LP
Treatments:
Antibodies, Monoclonal
Daratumumab